SUNDAY, JULY 12

12:45-16:15  
PRE-CongRESS WORKSHOPS  
Click here too see details

16:30-17:30  
SATellite SYMPOSIA  
Forum Hall  
Click here too see details

17:30-18:10  
OPENING CEREMONY  
Forum Hall

18:10-18:50  
OPENING LECTURES  
Forum Hall  
Chairpersons: D Furst (USA), T Krieg (DE)

• 18:10-18:30  
Two years in review, basic  
C Feghali-Botswick (USA)

• 18:30-18:50  
Two years in review, clinical  
C Denton (UK)

18:50-19:30  
WSF/ASF PROJECTS  
Forum Hall  
Chairpersons: S Assassi (USA), Y Asano (JP)

• 18:50-19:00  
Presentation of the winners  
M Matucci-Cerinic (IT), Mme Y Corcoux (FR)

• 19:00-19:10  
DEVELOPMENT OF THE OPTIMAL TOUCHSCREEN INTERFACE FOR PATIENTS WITH SCLERODERMA  
G Moroncini et al (IT)

• 19:10-19:20  
RANDOMIZED CONTROLLED TRIAL OF AN INTERNET-BASED EXERCISE PROGRAM TO IMPROVE HAND FUNCTION IN PATIENTS WITH SCLERODERMA: A SCLERODERMA PATIENT-CENTERED INTERVENTION NETWORK (SPIN) STUDY  
L. Kwakkenbos et al (NL)

19:20-19:30  
I’VE HANDED BACK MY MAN CARD: EXPERIENCES, COPING STYLES, AND SUPPORT PREFERENCES OF MEN WITH SSC  
C Flurey et al (UK)

19:30-20:00  
TAKEHARA’S PRIZE - WSF HONOURS PROFESSOR KAZUHIKO TAKEHARA FOR HIS OUTSTANDING CAREER  
Forum Hall  
Chairperson: K Takehara (JP)

• 19:40-19:50  
UNRAVELLING THE AETIOPATHOGENESIS OF MORPHOEA BY NEXT GENERATION SEQUENCING OF PAIRED SKIN BIOPSIES  
AM Saracino et al (UK)

• 19:50-20:00  
IMMUNIZATION OF MICE WITH HUMAN AT1R GENERATES AT1R-ACTivating ANTIBODIES AND INDUCES SSC-LIKE DISEASE  
F Petersen et al (DE)

20:00-21:30  
Welcome Reception  
Zoom room - first floor
MONDAY, JULY 13

08:00-09:20  SESSION 1 - PULMONARY  Forum Hall
Chairpersons: R Silver (USA), P Carreira (ES)

- 08:00-08:20
  How to screen and follow up SSc-ILD?
  A Prasse (DE)

- 08:20-08:40
  Group 3 PH, to treat or no to treat?
  S Gaine (IE)

- 08:40-08:50
  COMPUTED TOMOGRAPHY-BASED RADIOMICS FEATURES FOR DETECTION AND STAGING OF INTERSTITIAL LUNG DISEASE IN SSC - TRANSFERABILITY FROM EXPERIMENTAL TO HUMAN LUNG FIBROSIS
  J Schniering et al (CH)

- 08:50-09:00
  DISEASE COURSE OF PROGRESSIVE INTERSTITIAL LUNG DISEASE IN SSC: A 5-YEAR FOLLOW-UP FROM THE EUSTAR DATABASE
  A Hoffmann-Vold et al (NO)

- 09:00-09:10
  NEW HEMODYNAMIC DEFINITIONS OF PULMONARY HYPERTENSION: IS IT USEFUL IN SSC PATIENTS?
  A Volkov et al (RU)

- 09:10-09:20
  VEGF-C AND ITS RECEPTOR VEGFR-3 AS POTENTIAL SERUM BIOMARKERS FOR PULMONARY ARTERIAL HYPERTENSION IN SSC
  H Didriksen et al (NO)

09:25-10:35  Session 2 - HEART  Forum Hall
Chairpersons: A Vacca (IT), N Damjanov (RS)

- 09:25-09:45
  Screening for myocardial disease in SSc: which tools and when?
  C Buccarelli-Ducci (UK)

- 09:45-10:05
  Cardiac work-up in SSc: how to distinguish primary heart involvement from ordinary cardiovascular disease
  M Buch (UK)

- 10:05-10:15
  SERUM CARDIAC BIOMARKERS AND CARDIAC MRI DIFFUSE FIBROSIS MAY PREDICT THE DEVELOPMENT OF CARDIOVASCULAR EVENTS IN SYSTEMIC SCLEROSIS PATIENTS
  B Dumitru Raluca et al (UK)

- 10:15-10:25
  SSC MYOCARDITIS HAS UNIQUE CLINICAL, HISTOLOGICAL AND PROGNOSTIC FEATURES: COMPARATIVE ANALYSIS BETWEEN PATIENTS WITH ENDOMYOCARDIAL BIOPSY-PROVEN MYOCARDITIS
  G De Luca et al (IT)

- 10:25-10:35
  PRIMARY SYSTEMIC SCLEROSIS HEART INVOLVEMENT (PSSCHI): A SYSTEMATIC LITERATURE REVIEW (SLR) AND PRELIMINARY CONSENSUS-BASED DEFINITION
  C Bruni et al (IT)

10:35-11:05 • Coffee break

11:05-12:35 SATELLITE SYMPOSIA  Forum Hall
Click here too see details

12:35-13:40 Poster session and lunch

13:40-15:45 SATELLITE SYMPOSIA  Forum Hall
Click here too see details

15:45-16:15 • Coffee break

16:15-17:45 SPECIAL SYMPOSIUM  Forum Hall
HIGHLIGHTS IN SSC RESEARCH ACROSS JOURNALS: CONTRIBUTION FROM THE RECENT LITERATURE
Chairpersons: M Kuwana (JP), A Clark (UK), H van Epps (NL), J Varga (USA)

Journal of Scleroderma and Related Disorders
16:15-16:35
Adipose-derived mesenchymal stromal/stem cells in SSc: alterations in function and beneficial effect on lung fibrosis are regulated by caveolin-1
S Hoffman (USA)
MONDAY, JULY 13

Lancet Rheumatology
• 16:35-16:55
Evidence-based consensus statements for the identification and management of interstitial lung disease in SSc
A Hoffmann-Vold (NO)

Lancet Respiratory Medicine
• 16:55-17:15
Nintedanib in patients with progressive fibrosing interstitial lung diseases: subgroup analyses by interstitial lung disease diagnosis in the randomised, placebo-controlled INBUILD trial
A Wells (UK)

Arthritis & Rheumatology
• 17:15-17:35
The best highlights from A&R in 2019
J Varga (USA)

17:45-18:15  Forum Hall
HORIZON 2020
THE BEST FROM THE DESSCIPHER PROJECT
Chairpersons: L Czirjak (HU), F van den Hoogen (NL)

• 17:45-17:50
Introduction into the Desscipher Project
U Mueller-Ladner (DE)

• 17:50-18:00
Activity Indices and individualized Immunosuppression
V Lorand (HU)

• 18:00-18:10
Functional Disability and Digital Ulcers
V Jaeger (DE)

• 18:10-18:15
Myocardium & Summary
U Mueller-Ladner (DE)

18:15-19:15  Forum Hall
PARALLEL SESSION 3 - BASIC
Chairpersons: A Gabrielli (IT), J Distler (DE)

• 18:15-18:35
Can tissue transcriptome be used for patients stratification?
F Del Galdo (UK)

18:35-18:55
Update on circulating Biomarkers
M Kuwana (JP)

18:55-19:05
MACHINE-LEARNING CLASSIFICATION IN THE ABATACEPT IN SYSTEMIC SCLEROSIS TRIAL (ASSET) IDENTIFIES A SUBSET OF PATIENTS THAT IMPROVE ON THERAPY VIA MODULATION OF A CD28-RELATED PATHWAY
M Whitfield et al (USA)

19:05-19:15
LARGE-SCALE EXAMINATION OF LONGITUDINAL SKIN GENE EXPRESSION AND ITS ASSOCIATIONS WITH SKIN THICKNESS IN SSC
B Skaug et al (USA)

19:15-19:25
SERUM INTERFERON SCORE PREDICTS WORSE CLINICAL OUTCOME AT 12 MONTHS IN DIFFUSE SSC AS MEASURED BY GLOBAL RANKED COMPOSITE SCORE (GRCS) AND ACR COMPOSITE RESPONSE INDEX IN SSC (CRISS)
F Del Galdo et al (UK)

19:25-19:35
INTERFERON CHEMOKINE SCORE PREDICTS RESPONSE TO TREATMENT IN SSC RELATED INTERSTITIAL LUNG DISEASES
S Assassi et al (USA)
MONDAY, JULY 13

19:05-19:15
NAILFOLD CAPILLARY MICROSCOPY HAS LIMITED PROGNOSTIC VALUE IN PREDICTING FUTURE DEVELOPMENT OF CONNECTIVE TISSUE DISEASE IN CHILDREN WITH RAYNAUD’S PHENOMENON

G Van der Kamp et al (AN)

TUESDAY, JULY 14

08:00-09:00
MEET THE PROFESSOR SESSIONS

SRC Room 221
V Steen (USA)

Skin beyond fibrosis
T Krieg (DE)

How to interpret cardiac echo
and right heart catheterism
C Bucciarelli-Ducci (UK)

Difficult GI complications
SL Chatzinikolaou (UK)

How to manage early DcSSC
M Mayes (USA), J Pope (CA)

09:00-10:00
PARALLEL SESSION 5 - CLINICAL

Chairpersons: S Bosello (IT), M Hughes (UK)

09:00-09:10
PROVISIONAL AMERICAN COLLEGE OF RHEUMATOLOGY (ACR) COMBINED RESPONSE INDEX IN DIFFUSE CUTANEOUS SSC (CRiSS) SCORE CORRELATES WITH CHANGES <DELTA> IN PATIENT-REPORTED OUTCOMES (PRO)

R Spiera et al (USA)

09:10-09:20
THE EFFECT OF GENDER ON OUTCOME IN SSC: DOES ANTI-TOPOISOMERASE I AUTOANTIBODY (ATA) MATTER?

J De Vries-Bouwstra et al (NL)

09:20-09:30
THE PATIENT JOURNEY OF SSC-ILD IN EUROPE: AN INTEGRATED ANALYSIS OF HEALTHCARE PROFESSIONAL AND PATIENT PERSPECTIVES

A Hoffmann-Vold et al (NO)

09:30-09:40
THE TIMELINESS AND TYPES OF CANCER IN SSC

K Gunnarsson (SE)

09:40-09:50
THE RELATIONSHIP BETWEEN GASTROINTESTINAL SEVERITY AND SYMPTOMS AND WHOLE GUT TRANSIT IN PATIENTS WITH SSC

Z McMahan et al (USA)

09:50-10:00
VALIDATION OF DISEASE ACTIVITY MEASURES IN PATIENTS WITH JSSC - RESULTS FROM THE JSSC INCEPTION COHORT

I Foeldvari et al (DE)

09:00-10:00
PARALLEL SESSION 6 - BASIC

Chairpersons: ME Truchetet (FR), M Tomcik (CZ)

09:00-09:10
FGFR3/FGF9 SIGNALING REGULATES A NETWORK OF PROFIBROTIC CYTOKINE AND GROWTH FACTOR PATHWAYS TO DRIVE FIBROBLAST ACTIVATION AND TISSUE FIBROSIS IN SSC

D Chakraborty et al (DE)

09:10-09:20
A NOVEL HUMANIZED MODEL FOR SSC BY TRANSFERRING PBMC FROM PATIENTS INTO IMMUNODEFICIENT MICE

X Yu et al (DE)

09:20-09:30
FLI1-DEFICIENT ADIPOCYTES PROMOTE SPONTANEOUS SKIN FIBROSIS AND VASCULOPATHY: POTENTIAL ROLES OF ADIPOCYTES IN SSC

T Miyagawa et al (JP)

09:30-09:40
ADENO-ASSOCIATED VIRUS-5 TARGETS PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA IN LUNG AND PERIPHERAL BLOOD OF PATIENTS WITH SYSTEMIC SCLEROSIS AND ELICITS STIMULATORY ANTIBODIES

A Gabrielli et al (IT)

09:40-09:50
IMMUNE MECHANISMS OF DISORDER IN THE WORK OF THE BODY’S ANTIOXIDANT SYSTEM IN THE PATHOGENESIS OF LUNG DAMAGE IN SSC

L Shilova et al (RU)
TUESDAY, JULY 14

• 09:50-10:00
TGFBRII-FC REDUCES FIBROSIS AND IMPROVES LUNG FUNCTION IN FOS-RELATED ANTIGEN-2 TRANSGENIC MICE, A MODEL OF SSC
G Li et al (USA)

10:00-10:30 Forum Hall
THE DEBATE: NEW TREATMENTS ON THE HORIZON
Chairpersons: M Baron (CA), V Steen (USA)

Nintedanib versus tocilizumab for treating SSc-ILD
O Distler (CH) vs D Khanna (USA)

10:30-11:00 • Coffee break

11:00-12:20 Forum Hall
SESSION 7 - SPECIAL ISSUES
Chairpersons: T Medsger (USA), G Riemekasten (DE)

• 11:00-11:20
SIBO: screening, diagnosis and treatment by a gastroenterologist
SL Chatzinikolaou (UK)

• 11:20-11:40
How imaging has improved the management of scleroderma in the last 10 years
M Vonk (NL)

• 11:40-12:00
The role of rehabilitation and exercising in the management of the various SSc manifestations
N Mugii (JP)

• 12:00-12:20
Vaccination of patients with autoimmune diseases: lights and shadows
P Bonanni (IT)

12:25-12:55 SATELLITE SYMPOSIA
Click here too see details

12:55-14:00
Poster session & lunch

14:00-14:30 SATELLITE SYMPOSIA
Click here too see details

14:30-15:20 Forum Hall
SESSION 8 - SKIN
Chairpersons: E Kucharz (PL), R Becvar (CZ)

• 14:30-14:50
Outcomes regarding skin involvement: performance of mRSS and measurement of skin fibrosis beyond mRSS
J Pope (CA)

• 14:50-15:00
BIOSAMPLES FROM AT RISK SSC PATIENTS SHOW CLASSIC PATHOLOGICAL SIGNS OF SCLERODERMA: OPPORTUNITY FOR A DIAGNOSIS OF PRE-CLINICAL SSC.
R Ross et al (UK)

• 15:00-15:10
OPTICAL COHERENCE TOMOGRAPHY OF THE SKIN DETECTS SCLERODERMA CHANGES IN CLINICALLY UNAFFECTED SKIN: AN OPPORTUNITY FOR EARLY DETECTION OF SSC
G Abignano et al (IT)

• 15:10-15:20
EXPLORING ASSOCIATION BETWEEN SKIN SCORE TRAJECTORY, SURVIVAL AND PULMONARY OUTCOME IN DIFFUSE CUTANEOUS SSC
S Nihtyanova et al (UK)

15:20-16:20 Forum Hall
SESSION 9 - AUTOIMMUNITY FORUM
Chairpersons: A Balbir-Gurmann (IL), H Yasuoka (JP)

• 15:20-15:40
Why we develop overlapping autoimmune diseases
Y Shoenfeld (IL)

• 15:40-16:00
Antisynthetase syndrome
L Cavagna (IT)

• 16:00-16:20
Autoantibodies in interstitial lung disease and autoimmune rheumatic conditions
X Bossuyt (BE)
16:20-17:40

SESSION 10 - THERAPY

Chairpersons: L Chung (USA), E Volkmann (USA)

• 16:20-16:40
Progresses in the treatment of SSc- five examples from real life
M Hinchcliff (USA)

• 16:40-16:50
DOES DOSE ADJUSTMENT AFFECT DECLINE IN FORCED VITAL CAPACITY IN PATIENTS TREATED WITH NINTEDANIB? DATA FROM THE SENSCIS TRIAL
M Mayes et al (USA)

• 16:50-17:00
INTENSIFIED IMMUNOSUPPRESSION COMBINED WITH PLASMAPHERESIS HAS FAVORABLE LONG TERM EFFECTS IN PATIENTS WITH EARLY-ONSET PROGRESSIVE SSc-INTERSTITIAL LUNG DISEASE
J Potjewijd et al (NL)

• 17:00-17:10
RELATIONSHIP OF BASELINE MEASURES TO THE CHANGE IN THE FORCED VITAL CAPACITY IN A PHASE 3 RANDOMIZED CONTROLLED TRIAL OF TOCILIZUMAB FOR THE TREATMENT OF EARLY SSc
D Khanna et al (USA)

• 17:10-17:20
SAFETY AND EFFICACY OF ABATACEPT IN EARLY DIFFUSE CUTANEOUS SSc: RESULTS FROM THE OPEN-LABEL EXTENSION OF A PHASE II INVESTIGATOR-INITIATED RANDOMIZED CONTROLLED TRIAL
L Chung et al (USA)

• 17:20-17:30
RISK FACTORS AND LONG-TERM FOLLOW UP OF PATIENTS WITH SYSTEMIC SCLEROSIS TREATED WITH OR WITHOUT HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THE GERMAN NETWORK FOR SYSTEMIC SCLEROSIS
N Blank et al (DE)

• 17:30-17:40
ROICIGUAT IN PATIENTS WITH EARLY DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS AND INTERSTITIAL LUNG DISEASE: RESULTS FROM THE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE IIB STUDY (RISE-SSC)
O Distler et al (CH)